Use of Ultrasonic Bone Surgery (Piezosurgery) to Surgically Treat Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ). A Case Series Report with at Least 1 Year of Follow-Up

Cornelio Blus¹,², Serge Szmukler-Moncler¹,³, Giulio Giannelli⁴, Gloria Denotti¹ and Germano Orrù¹,*

¹OBL, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy
²Private Practice, Torino, Italy
³Galeazzi Orthopaedic Institute, Department of Odontology, University of Milano, Milano, Italy
⁴Department of Odontology, Hospital of Gallipoli, Gallipoli, Italy

Abstract: This preliminary work documents the use of a powerful piezosurgery device to treat bisphosphonate-related osteonecrosis of the jaw (BRONJ) in combination with classical medication therapy. Eight patients presenting 9 BRONJ sites were treated, 2 in the maxilla and 7 in the mandible. Reason for bisphosphonate (BiP) intake was treatment of an oncologic disease for 5 patients and osteoporosis for 3. The oncologic and osteoporosis patients were diagnosed with BRONJ after 35-110 months and 80-183 months of BiP treatment, respectively. BRONJ 2 and 3 was found in 4 patients. Resection of the bone sequestrae was performed with a high power ultrasonic (piezo) surgery and antibiotics were administered for 2 weeks. Soft tissue healing was incomplete at the 2-week control but it was achieved within 1 month. At the 1-year control, soft tissue healing was maintained at all patients, without symptom recurrence. One patient with paraesthesia had abated; of the 2 patients with trismus, one was healed, severity of the second trismus abated. This case report series suggests that bone resection performed with a high power ultrasonic surgery device combined with antibiotics might lead to BRONJ healing. More patients are warranted to confirm the present findings and assess this treatment approach.

Keywords: Piezosurgery, Ultrasonic bone surgery, Bone infection, Osteonecrosis, Bisphosphonates, BRONJ, Biofilm, ONJ.

INTRODUCTION

Biphosphonates (BiPs) have been a treatment of choice for a variety of diseases. It includes osteoporosis, skeletal-related events associated with bone metastases of solid tumors such as cancer of breast, prostate and lung, and management of lytic lesions in the setting of multiple myeloma [1-5]. Although BiPs do not improve cancer-specific survival, they significantly affect the life quality of patients suffering from advanced cancer involving the skeleton. Similarly, the clinical efficacy of oral BiPs for the treatment of osteopenia/osteoporosis has been well established. Up to 2007, over 225 million oral BiPs prescriptions have been dispensed worldwide [6].

According to the type of disease, BiPs are administered through various ways, oral, parenteral or intra-venous. Oral intake is preferred to overcome osteoporosis, while intra-venous intake is given to tumoral patients [3, 7].

Osteonecrosis of the jaws (ONJ) have been recently linked to BiP treatment. Frequency of BRONJ has been found to vary between 1/10,000 to 1/100,000. Patients receiving oral bisphosphate therapy are at a considerably lower risk of BRONJ than cancer patients treated with monthly IV bisphosphonates [8].

Oral and maxillofacial surgeons were the first to report non-healing cases of exposed bone in the maxillofacial region in patients treated with IV bisphosphonates [9, 10]. Generally, radiographic examination connected to soft tissue infection reveals images of bone necrosis with evidence of bone sequestrate [11].

Attention is usually drawn toward BRONJ when the 3 following characteristics are met [9]:

1. bone has been exposed to the oral cavity despite treatment for more than 8 weeks,
2. patient is treated or has been treated with BiPs,
3. patient has no history of radiation therapy to the jaws.

The classification of BRONJ according to stages has been recently revised by Ruggiero et al [9]. It is now the following:

Stage 0: No clinical evidence of necrotic bone, however nonspecific clinical findings and symptoms are present,
Table 1. Detail of the Treated Patients and Related Information

| Nb | Pat | Sex | Age | Primary disease | BIP Treatment | Length of BIP treatment (months) | Triggering cause of BRONJ | Osteonecrotic area | ONJ Classification | Time between start of BIP intake and BRONJ diagnosis (months) | Time between end of BIP intake and BRONJ diagnosis (months) | Time between surgery and last follow-up (months) |
|----|-----|-----|-----|-----------------|---------------|-------------------------------|--------------------------|--------------------|-------------------|-----------------------------|-----------------------------------------------|-----------------------------------------------|
| 1  | MA  | F   | 79  | Breast cancer   | Zoledronate (Zometa) | 15                           | Extraction of # 43, 44   | Mandible, Left anterior area | ONJ 3             | 39                           | 0.5                                           | 27, deceased                        |
| 2  | IG  | F   | 77  | Osteoporosis    | Alendronate (Fosavance) | 35                           | Extraction of # 46       | Mandible, Posterior at # 46 | ONJ 2/3           | 88                           | 0                                             | 38                                           |
| 3  | DF  | M   | 68  | Multiple myeloma| Zoledronate (Zometa) | 38                           | Extraction of # 36,37,46,47 | Mandible, Bilat. posterior at # 36,37 & 46,47 | ONJ 3             | 110                          | 6                                             | 32                                           |
| 4  | BA  | M   | 77  | Prostate cancer | Zoledronate (Zometa) | 33                           | Traumatic ill-fitted prosthesis | Mandible, Anterior at # 33,34 | ONJ 2             | 90                           | 3                                             | 26                                           |
| 5  | SM  | F   | 81  | Osteoporosis    | Alendronate (Fosavance) | 32                           | Extraction of # 11,12   | Maxilla, Anterior at # 11,12 | ONJ 2             | 80                           | 0                                             | 23                                           |
| 6  | GP  | M   | 60  | Multiple myelome| Zoledronate (Zometa) | 20                           | Extraction of # 16,17   | Maxilla, Posterior at # 16,17 | ONJ 3             | 53                           | 1                                             | 15                                           |
| 7  | NL  | F   | 69  | Osteoporosis    | Alendronate (Alendron 70) | 70                           | Extraction of # 47       | Mandible, Posterior at # 47 | ONJ 2             | 183                          | 3                                             | 14                                           |
| 8  | MS  | F   | 59  | Multiple myelome| Zoledronate (Zometa) | 13                           | Extraction of # 43,44   | Mandible, Left anterior area | ONJ 2             | 35                           | 1                                             | 13                                           |

Stage 1: Exposed and necrotic bone in asymptomatic patients without evidence of infection.

Stage 2: Exposed and necrotic bone associated with infection as evidenced by pain and erythema in region of exposed bone or with purulent drainage.

Stage 3: Exposed and necrotic bone in patients with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone, (i.e. inferior border and ramus in the mandible, maxillary sinus and zygoma in the maxilla) resulting in pathologic fracture, extraoral fistula, oral antral/oral nasal communication, or osteolysis extending to the inferior border of the mandible or the sinus floor.

When BRONJ class 1 is confirmed, the treatment consists of symptomatic treatment with oral antibiotics, oral antibacterial mouth rinse with chlorhexidine, pain control and superficial debridement to relieve soft tissue irritation. When BRONJ classes 2 or 3 are assessed, the same as above is tried. When it fails, the treatment is more aggressive; it involves surgical debridement/resection for longer term palliation of infection and pain [9]. In all cases, soft tissue healing is not easily achieved after surgery.

Several methods have been implemented to try to regulate soft tissue and bone healing, they are medication [11, 12], surgical resection [13-17], hyperbaric oxygen therapy [18], laser biostimulation [13, 14], autologous platelet-rich plasma [19]; but their efficiency could not be proven [9, 20]. Surgeons often feel powerless with this severe disease [17, 20].

The aim of the present case report series is to document the application of ultrasonic surgery as a new surgical tool to treat BRONJ patients that did not respond to medical treatment alone. A follow-up of at least 1 year was introduced in order to check for recurrent symptoms.

MATERIALS AND METHODOLOGY

Patient Enrollment in the Present Case Series

Inclusion criteria in the present case series were: (i) patients were diagnosed with BRONJ at various stages of clinical progression (Table 1), (ii) after they did not respond to classical medical treatment, patients were planned for surgical treatment. Surgery was performed by using vibrating tips connected to a high power ultrasonic (piezo) device, (iii) patients had to be followed for at least 12 months after surgery in order to be able to check for recurrent symptoms. This excluded patients that died earlier because of their primary oncologic disease or were prevented to attend because of their general health situation.

From January 2008, eight consecutive patients entering the inclusion criteria were treated in Gallipoli Hospital (Gallipoli, Puglia, Italy) for BRONJ by a single oral surgeon (GG); they were 5 women and 3 men, mean age was 71.3 ± 8.6 (range 59-81). Six mandibles were diagnosed with os-
Tineonecrosis, 3 in the anterior region and 3 in the posterior; in the maxilla, one was in the anterior region and one in the posterior. One mandible had bilateral necrosis in the posterior area; overall 9 sites were treated. Dental events having triggered osteonecrosis were tooth extraction in 7 patients and an ill-fitting prosthesis in 1 of them (Table 1).

Patients have been under BiP treatment for different reasons: 5 to treat various neoplastic diseases associated with metastatic bone lesions and 3 for osteoporosis (Table 1). Five patients received Zoledronate (Zomet, Novartis Farma, Orrigio, Italy) and 3 received Alendronate; 2 as Fosavance (Merck, Sharp & Dohme, Rome, Italy) and 1 as Alendros 70 (Abiogen Pharma SpA, Pisa, Italy). All tumoral patients (Table 1) were treated with chemotherapy, immunodepression or hormonal therapy. BiP intake lasted for an average of 32.0 ± 18.1 months (range 15-38 months). Osteonecrosis was diagnosed 84.5 ± 47.6 months in average (range 15-110 months) after initiation of BiP intake and 2.8±2.4 months in average (range 0-6 months) following the end of the BiP treatment. Two patients were diagnosed with osteonecrosis during the BiP treatment; intake was subsequently interrupted (Table 1).

### Treatment Protocol

When osteonecrosis was diagnosed (Table 1), conservative Chlorhexidine 0.2% rinsing was recommended two times per day and an antibiotic therapy cycle of 2 x 2 weeks separated by 1 week was administrated; it consisted of amoxicillin and Clavulanic acid (2g/d) and Metronidazole (1g/d) [20]. If gingival healing was not achieved, surgical treatment was considered.

### Symptoms and Clinical Signs

Symptoms and clinical signs were recorded for each patient before surgery and thereafter at the various milestones (Table 2). Patients treated for osteoporosis showed osteonecrosis superposed with infection, recalling osteomyelitis. With the oncology patients, infection appeared as the result of exposure of bone. Trismus was found at 2 patients, one of them was slight; another patient suffered from paraesthesia (Table 2).

### Piezosurgery Device

The surgical treatment was performed with the UBS device (Resista, Omegna, Italy), a powerful piezosurgery device with titanium alloy tips [21, 22] (Fig. 1a, 1b) and a peak power of 90 W [22].

Activation of the ultrasonic device leads to cavitation and the latter may have a killing effect on bacteria in suspension [23, 24]. It has been attributed to membrane rupture following numerous cycles of powerful bubble explosions at the vicinity of the living germs.

Three vibrating types of tips (Fig. 1b) were implemented with the power set at 72 W (level 5 out of 9) [24]. The bone scraper tip served to remove the superficial necrotic bone. The 2 saws, a straight and an orthogonal one, were used to separate the bone sequestrae. The 2 round tips, a short for the anterior area and a long straight one to easily access the posterior vestibular and lingual sectors were convenient to smooth down the sites before soft tissue closure.

### Medical Protocol

Antibiotic therapy (amoxicillin and Clavulanic acid 2g/d and Metronidazole 1g/d) was implemented for 2 weeks, starting 1 day before ultrasonic surgery.

### Ultrasonic Surgery Protocol

Following a loco-regional anesthesia with Mepivacaine chlorhydrate without vasoconstrictors (Optocain, Molteni
BRONJ Treatment with Piezosurgery

The Open Dentistry Journal, 2013, Volume 7

dental, Scandicci, Italy), a flap was raised and the soft tissues were reclined to provide full access to the bone. Bone was resected with the various vibrating tips.

**Follow-up and Success Criteria**

After surgery, patients were controlled 2 weeks after surgery, at 1 month, 6 months, 1 year and then for the need of the present report; patients could also attend in case they needed. Symptoms and clinical signs were assessed at each visit; orthopantomograms were taken to get radiological information at 6 months and later.

Clinical success criteria were: (i) symptom abatement or complete resolution, (ii) soft tissue coverage of the exposed bone, (iii) healthy soft tissue at the treated sites. X-ray examination was not part of the assessment because the indication of healing cannot be proven radiologically [16].

**RESULTS**

During surgery, local bone finding was different according to the reason for BiP treatment, osteoporosis or neoplasm. With the osteoporotic patients, necrotic bone was not as extensive as for the oncology patients; it was rather disseminated among vital bone. In this case, the bone scraper tip and the round one were used to remove the necrotic non-bleeding areas. At the cancer patients, the necrotic bone was scraped and the bone sequestra were then sectioned with the straight and the orthogonal saws. Bone was further removed with the bone scraper and the round tips until bleeding was assessed all over the remaining bone. Overall, the local tissues were exposed to several minutes of powerful cavitation. The granulation tissue was removed and a gingivoplasty was performed before suturing the gingiva. In all cases, primary intention closure was obtained.

Histological sampling confirmed osteonecrosis and infiltration of lymphoplasma cells; 2 patients suffered from mycosis in addition of osteonecrosis.

Figs. (2-4) are showing some of the treated cases. Table 2 provides the symptoms recorded for each patient and their progress following surgery. At the 2-week control, healing was delayed, still incomplete but ongoing. At the 1-month control, all symptoms either abated or disappeared (Table 2). The gingiva was healthy and covered the treated area; a slight invagination was observed, probably due to a loss of bone support. In one patient out of 2, the recorded trismus abated but persisted. In the patient that suffered from paraesthesia the severity was reduced. At the 6-month and 1-year controls, the gingivae were healthy without recurrent symptoms. Average follow-up was 23.0 months (min 12 m, max 38 m), one patient deceased after the last control at 27 months.

**DISCUSSION**

In the hospital environment where patients were treated, the cancer patients receiving BiPs have had a high mortality, shortly after treatment of the BRONJ symptoms. It is therefore rather difficult to evaluate the success of the management over time. This is the reason why this case series focused only on patients that could be followed for at least 1 year.

As previously reported by others [25, 26], patients that received BiPs for oncologic reasons had more advanced necrosis than patients treated for osteoporotic reasons.

Several methods have been tried to boost the healing of the soft and hard tissues involved in the BRONJ symptoms [12-19]. Usually, they are aiming at eliminating pain and the other clinical symptoms, control the local infection, minimize the progression of bone necrosis and avoid repetition of necrosis.

For the first time, ultrasonic bone surgery was applied to the BRONJ patient in need of surgical treatment. The assumption of a helpful application toward abating or healing the infectious aspect of the syndrome was drawn from the
Fig. (2). Treatment of a BRONJ case in the mandible.

a. Preoperative clinical situation. ONJ 3 has been diagnosed after 110 months of Zoledronate intake to treat multiple myeloma. Tooth extraction was considered as the triggering event.

b. Radiographic examination. Note the large necrotic area in the posterior region.

c. Section of the sequestrum with the vibrating tips of the piezosurgery device.

d. Bone sequestrum and soft tissue removed by the vibrating tips.

e. Healing at 1 month. The soft tissues are showing invagination.

f. One-year control. Healing of the necrotized and infected area is complete.
Fig. (3). Treatment of a BRONJ case in the mandible.

a. Preoperative clinical situation. ONJ 3 has been diagnosed after 72 months of Alendronate treatment for osteoporosis. Tooth extraction was considered as the triggering event.

b. Preoperative radiograph. Note the area of necrotic bone at the right second molar site in the mandible.

c. Surgical section of the sequestrum with a vibrating tip of the ultrasonic surgery device.

d. Surgical site before soft tissue closing. Note the large defect and the site of the extracted first molar.

e. Healing at 1 month. The soft tissues are showing invagination.

f. One-year control. Note the complete healing of the site.

g. Radiograph at the 1-year control. Note the satisfactory radiologic aspect at the necrotized site.
bacteriocidal effect we previously observed in vitro on Gram positive (*Escherichia coli*) and Gram negative bacteria (*B. subtilis*) [24]. It came also from a previous positive result while treating the diabetic foot [27] and placing dental implants successfully in chronic and acute infected post-extraction sites after local ultrasonication [28].

An additional element was the findings of Preti *et al.* [29] while investigating the early stages of bone healing. These authors showed that more inflammatory cells were present in the bone samples prepared by drilling when compared to piezosurgery. Furthermore, the local increase in BMP-4 was earlier when the vibrating tips were applied [29].

In fact, the treatment that was applied in these patients is a combination of a medical protocol with antibiotics and a surgical one with a powerful piezosurgery device. The infected and necrotic tissues underwent a powerful cavitation effect during several minutes.

Some authors reported that microbial biofilms can be involved in the BRONJ process [30, 31]. Thus, the affected bone surface might offer an optimal microbial support, due to the coating process that develops between BiPs and hydroxyapatite [32]. Microbial aggregation might increase the inflammatory and necrosis status of the tissues [30-32].

In this context, application of ultra-sonic vibration and its related powerful cavitation might have decreased the microbial critical mass around the involved bone and allowed synergy with the medical treatment. This would be in line with the report that showed low-frequency surface acoustic waves being able to eradicate biofilm-residing bacteria by > 85% when applied simultaneously with an antibiotic in three clinically relevant species: *Escherichia coli*, *Staphylococcus epidermidis* and *Pseudomonas aeruginosa* [33].

In these patients, tooth extraction had a triggering effect on bone necrosis. The above arguments related to biofilm disruption could suggest that performing extraction with the vibrating tips might have avoided or at least abated such triggering effect. For this purpose, it might also be appropriate to add 2 minutes of ultrasonication of the socket to carefully clean all its walls. But all that needs further confirmation.

In this case series, healing was incomplete after 2 weeks but still progressing toward closure of the gingiva. At the 1-month control, complete closure of the surgical wounds was observed in addition to the disappearance of swelling and the other symptoms described in Table 2. A slight trismus persisted up to the 1 year control. The reason for these successful results is not fully understood; but the assumptions that led to apply ultrasonic surgery to treat this type of pathology might have been relevant.

**CONCLUSION**

In this work and for the first time, ultrasonic bone surgery was introduced as the surgical tool to successfully treat patients with BRONJ that needed surgical treatment. More patients are warranted to undergo the present combined medical and surgical protocol before drawing any conclusion. But the data should encourage further *in vivo/in vitro* experimental protocols about the involvement of ultrasonic surgery into the treatment of BRONJ.

**CONFLICT OF INTEREST**

The authors confirm that this article content has no conflicts of interest.

**ACKNOWLEDGEMENTS**

The authors want to thank doctorando Fourouzan Shapourovna Sebanoff for her active assistance during the conception of the paper.

**REFERENCES**

[1] Hortobagyi GN, Theriault RL, Lipton A, *et al.* Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16(6):2038-44.

[2] Major P, Lortholary A, Hon J, *et al.* Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a
pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19(2):558-67.

[3] Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20(17):3719-36.

[4] Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100(12):2613-21.

[5] Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96(11):879-82.

[6] Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 2009;67(5 Suppl):35-43.

[7] Sorensen OH. [Bisphosphonates—a new treatment in osteoradionecrosis]. Ugeskr Laeg 1991; 153(10):693-4.

[8] Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park) 2006; 20(9):1053-62; discussion 65-6.

[9] Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrrotla B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009;35(3):119-30.

[10] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-7.

[11] Moretti F, Pellecignni GA, Montebagnoli L, Marchetti C. A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112(6):777-82.

[12] Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy: a critical review. Minerva Stomatol 2010; 59(4):181-203, 4-13.

[13] Vescovi P, Merigo E, Meleti M, Fornaini C, Nammour S, Manfredi M. Nd:YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 2007;45(8):628-32.

[14] Vescovi P, Merigo E, Manfredi M, et al. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg 2008;26(1):37-46.

[15] Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med 2012;41(3):214-21.

[16] Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):85-95.

[17] Stanton DC, Balasanic E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67(5):943-50.

[18] Freiberger J, Padilla-Burgos R, Chihoe AH, Kraft KH, Boneta O, Moon RE, Piantadosi CA. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65(7):1321-7.

[19] Curi MM, Cossaful GS, Koga DH, et al. Bisphosphonate-related osteonecrosis of the jaws—an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 2011;69(9):2465-72.

[20] Yoneda T, Hagino H, Sugimoto T, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010;28(4):365-83.

[21] Blus C, Szmukler-Moncler S. Split-crest and immediate implant placement with ultra-sonic bone surgery: a 3-year life-table analysis with 230 treated sites. Clin Oral Implants Res 2006;17(6):700-7.

[22] Blus C, Szmukler-Moncler S, Salama M, Salama H, Garber D. Sinus bone grafting procedures using ultrasonic bone surgery: 5-year experience. Int J Periodontics Restorative Dent 2008;28(3):221-9.

[23] Thacker J. An approach to the mechanism of killing of cells in suspension by ultrasound. Biochim Biophys Acta 1973;304(2):240-8.

[24] Blus C, Szmukler-Moncler S. Atraumatic tooth extraction and immediate implant placement with Piezosurgery: evaluation of 40 sites after at least 1 year of loading. Int J Periodontics Restorative Dent 2010;30(4):355-63.

[25] Khan N, Licata A, Rogers D. Intravenous bisphosphonate for hypercalcemia accompanying subcutaneous fat necrosis: a novel treatment approach. Clin Pediatr (Phila) 2001;40(4):217-9.

[26] Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006; 77(2):109-17.

[27] Blus C, Szmukler-Moncler S, La Rosa A, Moia R. Ultra-sonic debridement. A novel approach of scar debridement. Proceedings of the 2nd Congress of the World Union Wound Healing Societies, 2004, July 8-13, Paris, France, Poster AA 004, p. 181.

[28] Blus C, Szmukler-Moncler S, Khoury PM, Piras V, Orrù G. Imme- diate implants placed in infected and non-infected sites after atraumatic tooth extraction and placement with piezo-surgery (ultra- sonic surgery). Clin Implant Dent Relat Res 2013, 15: [Accepted for publication].

[29] Preti G, Martinasso G, Peirone B, et al. Cytokines and growth factors involved in the osseointegration of oral titanium implants positioned using piezoelectric bone surgery versus a drill technique: a pilot study in minipigs. J Periodontol 2007;78(4):716-22.

[30] Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008;66(4):767-75.

[31] Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 2009;140(10):1259-65.

[32] Ganguli A, Steward C, Butler SL, et al. Bacterial adhesion to bisphosphonate coated hydroxyapatite. J Mater Sci Mater Med 2005;16(4):283-7.

[33] Kopel M, Degtyar E, Banin E. Surface acoustic waves increase the biological behavior of human osteoblasts in vitro and in tantalum implants. J Biomed Mater Res 2005;72(3):62-7.